BSGM News
Featured News
Major Medical Centers Enter into Installation Agreements for Evaluation of BioSig PURE EP™ Systems
February 11, 2021
BSGM News
BioSig and Mayo Clinic Collaborate on New R&D Program to Develop Transformative AI and Machine Learning Technologies for its PURE EP™ System
February 2, 2021
BSGM News
ViralClear adds St. David’s HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19
June 5, 2020
BSGM News
ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research
April 23, 2020
BSGM News
Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxiv
April 14, 2020
BSGM News
Featured News
BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19
April 3, 2020
BSGM News
Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.
March 31, 2020
BSGM News
BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture
March 25, 2020
BSGM News
BioSig Completes 100th Patient Case with PURE EP(tm) System
February 19, 2020
BSGM News
BioSig Technologies Signs a New Licensing Agreement with Mayo Clinic
September 12, 2019
1
2
Sign Up & Get FREE News Alerts From FNM Today!
Sign Up
